# Sparstolonin B

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/sparstolonin-b
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-28
**Evidence Score:** 4 / 10
**Category:** Compound
**Also Known As:** SsnB, Sparganium stoloniferum extract compound, Isocoumarin from Sparganium stoloniferum, Sparstolonin-B, Bur-reed stilbene compound

## Overview

Sparstolonin B is a bioactive stilbene compound isolated from Sparganium stoloniferum, a traditional Chinese medicinal plant, that exerts [anti-inflammatory](/ingredients/condition/inflammation) and anticancer effects primarily by inhibiting Toll-like receptor (TLR) signaling pathways and suppressing NF-κB activation. Laboratory evidence indicates it can induce G2/M cell cycle arrest and trigger apoptosis in cancer cell lines through modulation of cyclin-dependent kinase activity and pro-apoptotic protein expression.

## Health Benefits

• [Anti-inflammatory](/ingredients/condition/inflammation) effects demonstrated in laboratory cell culture studies (preliminary evidence only)
• Cancer cell growth inhibition shown in neuroblastoma and prostate cancer cell lines (in vitro evidence only)
• Cell cycle arrest and apoptosis induction in cancer cells (laboratory studies only)
• Potential antioxidant properties affecting [oxidative stress](/ingredients/condition/antioxidant) markers (mechanistic studies only)
• Modulation of cellular signaling pathways involved in cell proliferation (preliminary in vitro evidence)

## Mechanism of Action

Sparstolonin B selectively inhibits Toll-like receptor 2 (TLR2) and TLR4 co-receptor signaling by disrupting lipid raft integrity, thereby suppressing downstream MyD88-dependent NF-κB and MAPK pathway activation and reducing [pro-inflammatory cytokine](/ingredients/condition/inflammation) production including TNF-α and IL-6. In cancer cell models, it downregulates cyclin B1 and CDC2 expression to induce G2/M cell cycle arrest while upregulating the pro-apoptotic proteins Bax and cleaved caspase-3, and downregulating anti-apoptotic Bcl-2. Some evidence suggests it also inhibits PI3K/Akt signaling, further contributing to its antiproliferative effects in neuroblastoma and prostate cancer cell lines.

## Clinical Summary

All current evidence for Sparstolonin B derives exclusively from in vitro cell culture studies and preclinical laboratory models; no human clinical trials have been conducted as of 2024. In neuroblastoma cell line studies, Sparstolonin B reduced cell viability in a dose-dependent manner with IC50 values reported in the low micromolar range (approximately 10–50 µM depending on cell line). Prostate cancer cell line experiments demonstrated significant apoptosis induction and cell cycle arrest at similar concentrations, though these doses have not been validated in animal or human models. The complete absence of pharmacokinetic, bioavailability, and toxicology data in humans means efficacy and safety claims cannot be substantiated beyond preliminary mechanistic observations.

## Nutritional Profile

Sparstolonin B (SsnB) is a purified bioactive isocoumarin compound isolated from Sparganium stoloniferum (a traditional Chinese medicinal herb), not a conventional food ingredient and therefore has no macronutrient, micronutrient, fiber, or caloric profile. As a small-molecule phytochemical with a molecular weight of approximately 338.35 g/mol and molecular formula C18H18O7, it is classified strictly as a bioactive secondary metabolite. Typical experimental concentrations used in laboratory studies range from 1–100 μM in cell culture systems. It exhibits lipophilic characteristics due to its isocoumarin scaffold, suggesting moderate membrane permeability and potential for oral bioavailability, though formal pharmacokinetic data in humans is not yet established. No vitamin, mineral, protein, fat, or carbohydrate content is applicable. Known bioactive properties center on its Toll-like receptor (TLR2 and TLR4) antagonist activity, selectively blocking lipopolysaccharide- and lipoteichoic acid-induced [inflammatory](/ingredients/condition/inflammation) signaling pathways. Antioxidant activity has been mechanistically linked to modulation of [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) pathways in vitro. Bioavailability data in humans is absent; animal model studies suggest hepatic first-pass [metabolism](/ingredients/condition/weight-management) is likely, but specific metabolite profiles have not been fully characterized in peer-reviewed literature as of early 2025.

## Dosage & Preparation

No clinically studied dosage ranges are available as human clinical trials have not been conducted. Laboratory studies have used varying concentrations dissolved in DMSO, but these cannot be translated to therapeutic human dosing. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

No human safety data, established dosage guidelines, or toxicology profiles exist for Sparstolonin B, as it has not been evaluated in clinical trials or formal human pharmacokinetic studies. Because it inhibits TLR-mediated immune signaling and NF-κB activation, theoretical interactions with immunosuppressant drugs (e.g., corticosteroids, tacrolimus) and [anti-inflammatory](/ingredients/condition/inflammation) medications are plausible and warrant caution. Pregnant and breastfeeding individuals should avoid Sparstolonin B entirely given the complete absence of safety data in these populations. Anyone considering experimental use should consult a qualified healthcare provider, particularly those on anticoagulants or chemotherapy agents, as interactions cannot be ruled out.

## Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses of Sparstolonin B have been conducted. All available evidence comes exclusively from in vitro cell culture studies and laboratory research focusing on cellular mechanisms in cancer cell lines and endothelial cells.

## Historical & Cultural Context

In traditional Chinese medicine, Sparganium stoloniferum has been used to regulate menstruation, promote milk production (galactosis), and induce [muscle relaxation](/ingredients/condition/sleep) (spasmolysis). The plant's rhizomes and tubers form the basis of these traditional applications, though specific historical preparation methods are not extensively documented.

## Synergistic Combinations

Curcumin, Green Tea Extract, Resveratrol, Quercetin, Boswellia

## Frequently Asked Questions

### What is Sparstolonin B and where does it come from?

Sparstolonin B is a stilbene-class polyphenolic compound isolated from the rhizomes of Sparganium stoloniferum, a plant used in traditional Chinese medicine primarily for blood stasis and pain conditions. It was identified and characterized in more recent pharmacological research as the likely bioactive agent responsible for some of the plant's historically observed anti-inflammatory properties. Its stilbene scaffold is structurally related to other bioactive polyphenols but possesses a distinct substitution pattern that contributes to its selective TLR inhibitory activity.

### Has Sparstolonin B been tested in humans?

No, Sparstolonin B has not been tested in any published human clinical trials as of 2024, and all available data come from in vitro cell culture experiments. There are no peer-reviewed human pharmacokinetic studies, meaning oral bioavailability, effective plasma concentrations, metabolism, and elimination half-life remain unknown in people. This places Sparstolonin B at a very early, preclinical stage of research, and no therapeutic claims can be responsibly made for human use.

### How does Sparstolonin B fight inflammation?

Sparstolonin B inhibits inflammation by selectively disrupting Toll-like receptor 2 and TLR4 signaling at the level of lipid raft membrane domains, preventing receptor clustering and subsequent activation of the MyD88 adaptor protein. This upstream blockade suppresses downstream transcription factor NF-κB nuclear translocation, reducing gene expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 in macrophage cell culture models. The compound's selectivity for TLR co-receptor signaling rather than broad immune suppression distinguishes it mechanistically from common anti-inflammatory drugs like NSAIDs or corticosteroids.

### Can Sparstolonin B kill cancer cells?

In laboratory cell line studies, Sparstolonin B has demonstrated cytotoxic and antiproliferative activity against neuroblastoma (SH-SY5Y) and prostate cancer (LNCaP, PC-3) cell lines at micromolar concentrations, inducing G2/M cell cycle arrest by downregulating cyclin B1 and triggering apoptosis through caspase-3 activation and Bax/Bcl-2 ratio modulation. However, these are strictly in vitro findings, and the ability of any compound to kill cancer cells in a dish does not reliably predict efficacy or safety in a living organism. No animal tumor model studies or human oncology trials have been published for this compound.

### Is Sparstolonin B available as a supplement?

Sparstolonin B is not widely available as a commercial dietary supplement and is primarily found as a research-grade chemical reagent sold to laboratories for experimental purposes. Because it lacks clinical trial data, established dosing, and regulatory approval in any jurisdiction, it does not meet the standards typically associated with consumer-grade supplements. Individuals should be cautious of any product claiming to contain Sparstolonin B, as purity, concentration, and safety cannot be assured without rigorous quality control standards and human safety data.

### What does the current research evidence show about Sparstolonin B's effectiveness?

Current evidence for Sparstolonin B is limited to laboratory and cell culture studies, with no human clinical trials completed to date. While preliminary research shows promise in reducing inflammation markers and inhibiting cancer cell growth in neuroblastoma and prostate cancer cell lines, these in vitro results do not necessarily translate to human efficacy. The gap between laboratory findings and proven human benefits means that Sparstolonin B remains an experimental compound rather than an established therapeutic agent. More rigorous clinical research would be needed to determine whether these laboratory effects produce real health benefits in people.

### What are the known safety concerns or potential side effects of Sparstolonin B?

Safety data for Sparstolonin B in humans is virtually nonexistent, as the compound has not undergone human clinical trials or systematic safety evaluations. The absence of human studies means potential side effects, toxicity thresholds, and adverse reactions remain unknown. Pregnant women, nursing mothers, children, and individuals with specific health conditions should avoid Sparstolonin B supplements until adequate safety data becomes available. Anyone considering this ingredient should consult a healthcare provider given the lack of established safety guidelines.

### What natural food sources contain Sparstolonin B?

Sparstolonin B is a specialized bioactive compound isolated primarily from Sparganophora verticillata (a traditional plant source), and it is not found in measurable amounts in common foods or typical dietary sources. Unlike widely distributed nutrients, Sparstolonin B would only be obtainable through targeted supplementation using purified extracts. There is no practical way to obtain meaningful amounts of this ingredient from food sources alone. This specialized nature of the compound further underscores why human nutritional data and safety testing remain limited.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*